# Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination

> **NCT04470310** · PHASE4 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 99 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Glimepiride
- **DRUG:** Alogliptin 25Mg Tab
- **DRUG:** Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet

## Key facts

- **NCT ID:** NCT04470310
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12-31
- **Primary completion:** 2019-05-20
- **Final completion:** 2021-08-31
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04470310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04470310, "Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04470310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*